What this trial measures

• Sustained Attention to Response Task (SART)Visit 1B (Week 1) and Visit 2B (Week 4)

  The SART is a task used to evaluate sustained attention and inhibitory control. Participants will complete the SART task on a laboratory computer. The computerized test will display 225 randomly selected numbers ranging between 1 and 9; these numbers appear in different sizes throughout the duration of the test and are displayed in white on a black screen. Participants will be instructed to respond when each number appears by pressing the space bar on the computer's keyboard while refraining from pressing the space bar when the number 3 appears. Total error score will be calculated by assessing the number of space bar presses when no key should've been pressed as well as absent presses when a key should've been pressed.

• Alternate Use Task (AUT)Visit 1B (Week 1) and Visit 2B (Week 4)

  The Alternate Use Task is used to evaluate creativity and divergent thinking. The task will be derived from the original paper version of the AUT, in which an everyday object will be randomly selected and presented to the participant, and the participant will be tasked with thinking of a possible use for the presented object. Participants will be instructed to think of novel and unique uses that would deviate from traditional uses of the presented object. Participants will be given a blank sheet of paper and be granted 2-minutes to write down as many uses as possible. In this modified version of the original test, participants will be screened for originality, fluency, and flexibility.

• Piper Fatigue Scale (PFS)Visit 1B (Week 1) and Visit 2B (Week 4)

  Participants will be asked to complete the Piper Fatigue Scale (PFS), a 27-question questionnaire that utilizes a Likert scale (1-10) to assess subdomains of behavioral, affective, sensory, and cognitive/mood attributes of fatigue. This version of the PFS is a subjective measure of fatigue using a 10-point Likert scale ranging from 0 - 10 with 0 indicating "No Distress" and 10 indicating "A Great Deal", "Mild" to "Severe", "Pleasant" to "Unpleasant", "Agreeable" to "Disagreeable", "Protective" to "Destructive", "Positive" to "Negative", "Normal" to "Abnormal", "Strong" to "Weak", "Awake" to "Sleepy", "Lively" to "Listless", "Refreshed" to "Tired", "Energetic" to "Unenergetic", "Patient" to "Impatient", "Relaxed" to "A Great Deal", "Exhilarated" to "Depressed", "Able to Concentrate" to "Unable to Concentrate", "Able to Remember" to "Unable to Remember", and "Able to Think Clearly" to "Unable to Think Clearly".

• Perceived Stress Scale (PSS)Visit 1B (Week 1) and Visit 2B (Week 4)

  Participants will be asked to complete the Perceived Stress Scale (PSS), a classic stress assessment tool used to gauge how different situations affect feelings and perceived stress. This version of the PSS is a subjective measure of stress using a 5-point Likert scale ranging from 0 - 4 with 0 indicating "Never", 1 indicating "Almost Never", 2 indicating "Sometimes", 3 indicating "Fairly Often", and 4 indicating "Very Often".

• Mindful Attention Awareness Scale (MAAS)Visit 1B (Week 1) and Visit 2B (Week 4)

  Participants will be asked to complete the Mindful Attention Awareness Scale (MAAS), a 15-item scale designed to assess the core characteristics of mindfulness. This version of the MAAS is a subjective measure of mindfulness using a 6-point Likert scale ranging from 1 - 6 with 1 indicating "Almost Always", 2 indicating "Very Frequently", 3 indicating "Somewhat Frequently", 4 indicating "Somewhat Infrequently", 5 indicating "Very Infrequently", and 6 indicating "Almost Never".

• Heart Rate Variability (HRV)Visit 1B (Week 1) and Visit 2B (Week 4)

  Heart rate variability (HRV) will be analyzed to determine the fluctuation in the time intervals between adjacent heartbeats to assess autonomic regulation of the heart. Resting HR and HRV were measured using the electrocardiograph (GE CASE Exercise Testing System Version 6.0, Chicago, Illinois). To measure HRV, the root mean square successive difference method (RMSSD) was used with the 10-second electrocardiogram reading. Based on the outcome of this assessment, participants with SDNN values below 50 ms will be classified as unhealthy, 50-100 ms will be classified as having compromised health, and above 100 ms will be classified as healthy.

• Handgrip DynamometryVisit 1B (Week 1) and Visit 2B (Week 4)

  Isometric grip strength will be measured by a Baseline 12-0286 Electronic Smedly Hand Dynamometer (Fabrication Enterprises, White Plains, NY). To begin the test, participants will stand upright in a relaxed position; their upper extremity peak isometric grip strength will be assessed with the shoulder in 180º of flexion, elbow at full extension, and wrist and forearm in a neutral position. When prompted, participants will squeeze the device with their dominant hand, delivering a maximal effort for 3-seconds, followed by relaxation. After 30-seconds, the test is run again. Three sets will be completed for this test, and the highest value (kg) is recorded for analysis.

• Pittsburgh Sleep Quality Index (PSQI)Visit 1A (Week 1) and Visit 2A (Week 4)

  Participants will be asked to complete the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a 19-question self-reported sleep quality screening tool broken up into 7 subcategories for scoring, such as subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.

• Serum Analysis - Brain-Derived Neurotrophic Factor (BDNF)Visit 1A (Week 1) and Visit 2A (Week 4)

  Approximately 40mL of whole blood will be collected into serum separator tubes (Beckton Dickinson, East Rutherford, NJ, USA), allowed to clot for 30-minutes at room temperature, then centrifuged at 2000 RPM for 15 min. The serum will be pipetted into 1.5 mL microcentrifuge tubes (Eppendorf AG, Hamburg, Germany) and immediately stored in a -80 °C freezer. Serum concentrations of BDNF (Sigma-Aldrich, St. Louis, MO, USA) will be determined with a commercially available enzyme-linked immunosorbent assays. Microplates will be read with an ELx800 BioTek microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at the recommended wavelength of 450 nanometers.

• Serum Analysis - CortisolVisit 1A (Week 1) and Visit 2A (Week 4)

  Approximately 40mL of whole blood will be collected into serum separator tubes (Beckton Dickinson, East Rutherford, NJ, USA), allowed to clot for 30-minutes at room temperature, then centrifuged at 2000 RPM for 15 min. The serum will be pipetted into 1.5 mL microcentrifuge tubes (Eppendorf AG, Hamburg, Germany) and immediately stored in a -80 °C freezer. Serum concentrations of cortisol (ALPCO Diagnostics, Salem, NH, USA) will be determined with a commercially available enzyme-linked immunosorbent assays. Microplates will be read with an ELx800 BioTek microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at the recommended wavelength of 450 nanometers.

• Serum Analysis - Nerve Growth Factor (NGF)Visit 1A (Week 1) and Visit 2A (Week 4)

  Approximately 40mL of whole blood will be collected into serum separator tubes (Beckton Dickinson, East Rutherford, NJ, USA), allowed to clot for 30-minutes at room temperature, then centrifuged at 2000 RPM for 15 min. The serum will be pipetted into 1.5 mL microcentrifuge tubes (Eppendorf AG, Hamburg, Germany) and immediately stored in a -80 °C freezer. Serum concentrations of NGF (RayBiotech, Norcross, GA, USA) will be determined with a commercially available enzyme-linked immunosorbent assays. Microplates will be read with an ELx800 BioTek microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) at the recommended wavelength of 450 nanometers.